Key Insights

Highlights

Success Rate

87% trial completion (above average)

Published Results

15 trials with published results (19%)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

7.8%

6 terminated out of 77 trials

Success Rate

87.2%

+0.7% vs benchmark

Late-Stage Pipeline

5%

4 trials in Phase 3/4

Results Transparency

37%

15 of 41 completed with results

Key Signals

15 with results87% success

Data Visualizations

Phase Distribution

43Total
Not Applicable (13)
Early P 1 (1)
P 1 (10)
P 2 (15)
P 3 (2)
P 4 (2)

Trial Status

Completed41
Active Not Recruiting9
Recruiting9
Unknown8
Terminated6
Withdrawn2

Trial Success Rate

87.2%

Benchmark: 86.5%

Based on 41 completed trials

Clinical Trials (77)

Showing 20 of 20 trials
NCT01362803Phase 1Active Not Recruiting

AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors

NCT04763109Not ApplicableRecruitingPrimary

Identification of Pre-Malignant Lesions In Pediatric Patients With Neurofibromatosis Type 1 Using Novel Magnetic Resonance Imaging Techniques Paired With Artificial Intelligence

NCT03975829Phase 4Recruiting

Pediatric Long-Term Follow-up and Rollover Study

NCT07564622Not Yet RecruitingPrimary

Gait in Young Children With NF1

NCT00111384CompletedPrimary

Study of Disease Severity in Adults With Neurofibromatosis Type 1 (NF1)

NCT00924196Active Not RecruitingPrimary

Natural History Study of Patients With Neurofibromatosis Type I

NCT06880991RecruitingPrimary

Development of Patient-Reported Outcome Measures Assessing Tumor Visibility and Appearance Concerns in Neurofibromatosis Type 1: A Qualitative Study

NCT03050268Recruiting

Familial Investigations of Childhood Cancer Predisposition

NCT07221331RecruitingPrimary

Prevalence, Clinical Characteristics, Progression, and Management of Neurofibromatosis Type 1 in Egypt (NF1-Egy)

NCT00314119CompletedPrimary

Natural History and Biology of Skin Neurofibromas in Neurofibromatosis Type 1

NCT03190915Phase 2Active Not Recruiting

Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

NCT03871257Phase 3Active Not Recruiting

A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma

NCT06507748Not ApplicableRecruitingPrimary

A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1)

NCT06541847Phase 2RecruitingPrimary

A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1

NCT05388370Active Not RecruitingPrimary

PASS of Paediatric Patients Initiating Selumetinib

NCT05101148Phase 1Active Not RecruitingPrimary

Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas

NCT05954416Recruiting

FARD (RaDiCo Cohort) (RaDiCo-FARD)

NCT06515860RecruitingPrimary

Neurofibromatosis Type 1 Tumor Early Detection Study

NCT05309668Phase 1Active Not RecruitingPrimary

Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN

NCT05581511Active Not RecruitingPrimary

Natural History Study of Cutaneous Neurofibromas in People With NF1

Scroll to load more

Research Network

Activity Timeline